Advertisement

Topics

AZ talks up Bydureon data, GLP-1 and glucagon combo

19:48 EDT 14 Sep 2017 | pharmaphorum

AstraZeneca is hoping new data showing its Bydureon diabetes drug cuts overall death risk could stave off competition from Novo Nordisk's potential next generation GLP-1 drug. Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, i...

Original Article: AZ talks up Bydureon data, GLP-1 and glucagon combo

NEXT ARTICLE

More From BioPortfolio on "AZ talks up Bydureon data, GLP-1 and glucagon combo"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...